MIRMMirum Pharmaceuticals, Inc.

$5B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$19M

Net Income

-$18M

EPS (Diluted)

$-0.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$147M

Total Liabilities

$16M

Stockholders' Equity

$130M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$19M	-$4M	-334.0%
Net Income	-$18M	-$26M	+30.8%

MIRM Q4 2019 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena